Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
Calgary, Alberta--(Newsfile Corp. - August 12, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it...
Brain
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Hypha Labs Expands List of Functional Mushrooms Able to be Produced in its Revolutionary Mushroom Accelerator
Simple, In-Home Eight Day Cycle Generates Significant Yields of The World's Most Popular Mushroom Strains LAS VEGAS, NV / ACCESS...
Oragenics Q2 2025 Shareholder Update
Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics,...
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented...
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected...
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical...
Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11,...
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically...
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment...
FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156
• First Patient Dosing Expected in Q1 2026 • Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers KING OF PRUSSIA, Pa., Aug....
Sleep Lean Reviews (INVESTIGATED): What We Discovered After 90 Days of Testing Sleep and Weight Loss Results
MIAMI, FL / ACCESS Newswire / August 9, 2025 / When we first heard about Sleep Lean, our expectations were...
Luxury Hotel Innovates Wellness Tourism with Global-First Sleep Enhancement Offering
First-of-its-kind partnership between InterContinental Singapore and NuCalm brings cutting edge restorative travel to luxury travelers LOS ANGELES, Aug. 8, 2025 /PRNewswire/...
Is Audifort a Scam or the Real Natural Fix for Tinnitus and Hearing Loss? Latest Audifort Reviews Inside
CHICAGO, IL / ACCESS Newswire / August 8, 2025 / If that constant ringing in your ears is starting to...
Brain Computer Interface Market to Soar from USD 1.6 Billion in 2024 to USD 6.3 Billion by 2033, at 20.5% CAGR – Market Research Intellect
The Brain Computer Interface (BCI) market is experiencing rapid growth due to increasing advancements in neurotechnology, rising demand for assistive...
Eyesafe Report Finds the Average Person Will Spend 21 Years on Screens
MINNEAPOLIS, Aug. 7, 2025 /PRNewswire/ -- An individual born in 2025 is projected to spend 21 years of their life—equivalent...
Creyos Expands Session Notes to Turn Cognitive Health Testing Into Timely Clinical Action
Developed by world-renowned neuroscientist Professor Adrian Owen, Creyos helps providers detect cognitive impairment through a scientifically validated brain health assessment platform...
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction
New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential...
1.2 Million Healthcare Devices and Systems Found Exposed Online – Patient Records at Risk of Exposure, Latest Research from Modat
THE HAGUE, Netherlands, Aug. 7, 2025 /PRNewswire/ -- Over 1.2 million internet-connected healthcare devices and systems with exposure that endanger patient...
Midi Health Launches Its First-Ever Supplement Line Tailored to Women 40+
Clinician-Designed Supplements Fill a Critical Gap in Midlife Health With Formulas to Address the Most Common Symptoms Women Face PALO...